Can you provide the last earnings date for BONE BIOLOGICS CORP?
BONE BIOLOGICS CORP (BBLG) last reported earnings on 3/2/2026.
NASDAQ:BBLG • US0980706008
Past quarterly earnings results for BONE BIOLOGICS CORP (BBLG), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -0.14 | -0.35 | 59.63% | 96.20% | - | - | ||
| Q3 2025 | -0.37 | -1.25 | 70.51% | 97.40% | - | - | ||
| Q2 2025 | -1.33 | -0.59 | -124.81% | 66.92% | - | - | ||
| Q1 2025 | -1.92 | -2.94 | 34.64% | 75.57% | - | - | ||
| Q4 2024 | -3.68 | -3.98 | 7.39% | 75.14% | - | - | ||
| Q3 2024 | -14.22 | -3.67 | -287.25% | 51.43% | - | - | ||
| Q2 2024 | -4.02 | -8.51 | 52.74% | 82.55% | - | - | ||
| Q1 2024 | -7.86 | -46.51 | 83.10% | 97.63% | - | - | ||
| Q4 2023 | -14.82 | -34.27 | 56.76% | 94.28% | - | - | ||
| Q3 2023 | -29.28 | -148.84 | 80.33% | 83.06% | - | - | ||
| Q2 2023 | -23.04 | -73.44 | 68.63% | 68.00% | - | - | ||
| Q1 2023 | -331.20 | -102.82 | -222.13% | -228.57% | - | - | ||
| Q4 2022 | -259.20 | -330.48 | 21.57% | -3.81% | - | - | ||
| Q3 2022 | -172.80 | -220.32 | 21.57% | -101,547.06% | - | - | ||
| Q2 2022 | -72.00 | -176.26 | 59.15% | - | - | - | ||
| Q1 2022 | -100.80 | -293.76 | 65.69% | - | - | - | ||
| Q4 2021 | -249.70 | - | - | - | - | |||
| Q3 2021 | -0.17 | - | - | - | - | |||
| Q2 2021 | - | - | - | - | ||||
| Q1 2021 | - | - | - | - | ||||
| Q4 2020 | - | - | - | - | ||||
| Q3 2020 | - | - | - | - | ||||
| Q2 2020 | - | - | - | - | ||||
| Q1 2020 | - | - | - | - |
Notes
BONE BIOLOGICS CORP (BBLG) last reported earnings on 3/2/2026.
BONE BIOLOGICS CORP (BBLG) beat EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, BONE BIOLOGICS CORP (BBLG) has beaten EPS estimates in 3 out of 4 releases.